ClinicalTrials.gg
CompletedNCT01518946Updated Jun 8, 2021Results posted

Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension

A Phase 4 interventional study of Midodrine HCl and Placebo in Orthostatic Hypotension, sponsored by Shire. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-08.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing midodrine in Hypotension, Orthostatic — none open to participants now, none under way, none of them phase 3. Midodrine · Hypotension, Orthostatic.

Enrollment
11th of 16
24 · median 42
Started
2012
with 2 others
Phase 4
6 of 16
none open now
Registered
8th of 16
by date
Lead sponsor
5 of 16
Shire

Among the 16 studies testing midodrine in Hypotension, Orthostatic, this one is the 11th largest by enrollment, is one of 3 that started in 2012, is one of 6 in phase 4, and was the 8th registered.

Hypotension, Orthostatic

159 studies on the registry are indexed under Hypotension, Orthostatic; 35 are open to participants now.

Browse Hypotension, Orthostatic studies →

Open to participants now

None of the 16 studies testing midodrine in Hypotension, Orthostatic is open now. The open studies under Hypotension, Orthostatic, anywhere →

About midodrine

Midodrine: first FDA approval 1996 (PROAMATINE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 23 Hypotension, Orthostatic studies recruiting now, 8 (35%) set no upper age limit and 8 (35%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing midodrine in Hypotension, Orthostatic as a file.
02

Study summary

The purpose of this study is to determine whether midodrine works against the symptoms of orthostatic hypotension caused by being on a tilt table.

Read the detailed description

The efficacy of midodrine will be assessed in those subjects who have severe symptoms of orthostatic hypotension when not taking midodrine and are controlled when taking midodrine. The study will involve approximately 4 overnight stays.

03

Conditions studied

  • Orthostatic Hypotension

Keywords

  • Symptomatic Orthostatic Hypotension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects must be 18 years of age or older and ambulatory.
  2. Females of (FOCP) must have a negative serum beta human chorionic gonadotropin (HCG) pregnancy test.
  3. A documented history of severe Symptomatic Orthostatic Hypotension (SOH) that, in the judgment of the treating physician, has required treatment with midodrine HCl , and has been at a stable dose for at least 3 months.
  4. The subject has manifested at least 1 of the following symptoms while standing or had a medical history of 1 of the following when not treated for orthostatic hypotension (OH): dizziness, lightheadedness, feeling faint, or feeling like they might black out.

Exclusion criteria

Exclusion Criteria:

  1. The subject is a pregnant or lactating female.
  2. The subject has pre-existing sustained supine hypertension greater than 180mmHg systolic and 110mmHg diastolic BP or had these measurements at the Screening Visit. Sustained is defined as persistently greater at 2 separate measurements at least 5 minutes apart with the subject supine and at rest for the 5 minutes.
  3. Subjects taking concomitant medications of interest are excluded unless those medications are reviewed and discussed with the Medical Monitor or Study Physician and documented prior to enrolling the subject. If agreement is reached between the Investigator and Sponsor for the subject to continue in the study, all allowed medications should be maintained at a constant dose throughout the study.
  4. The Principal Investigator deems any clinical laboratory test (at the Screening Visit) abnormality to be
  5. The subject has participated in other studies of drugs or devices within 30 days prior to enrollment in this study (other than Study SPD426-406).
  6. Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the subject unlikely to fully comply with the requirements of the study or complete the study, or any condition that presents undue risk from the investigational product or study procedures.
  7. The subject has a concurrent chronic or acute illness, disability, or other condition (including significant unexpected laboratory or [ECG] findings) that might confound the results of the tests and/or measurements administered in this study, or that might have increased the risk to the subject.
  8. Known or suspected intolerance or to the investigational product(s), closely-related compounds, or any of the stated ingredients.
  9. Prior enrollment failure or randomization in this study.
  10. History of alcohol abuse or other substance abuse within the last year.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Midodrine HCl

    Drug: Midodrine HCl

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • dose at the subject's current dose level

    Also known as: ProAmatine®

  • DrugPlacebo

    single dose of matching placebo

06

What researchers measure

Primary outcomes

  1. Time to Onset of Syncope/Near Syncope While on Tilt Table

    After a 30-minute supine period, the table was tilted from 0-90º within 30 seconds and maintained in that position for 45 minutes or until endpoint. Subjects were monitored for near-syncopal symptoms (subject felt sufficiently dizzy, lightheaded, faint, or felt like they were about to black out and requested the table to be returned to horizontal). Such a report ended the test. Alternatively, if the investigator observed that the subject was about to lose consciousness, that also constituted an endpoint.

    Time frame: 1 hour post-dose

07

Results

Posted Jul 31, 2014

Participant flow

Open-label Phase
Participant flow — Open-label Phase
MilestoneMidodrine HCl (Open-label Phase)Placebo First, Then Midodrine HCl (Randomized Phase)Midodrine HCl First, Then Placebo (Randomized Phase)
Started2400
Completed2000
Not completed400
Withdrew: Other400
Randomized Phase (First Intervention)
Participant flow — Randomized Phase (First Intervention)
MilestoneMidodrine HCl (Open-label Phase)Placebo First, Then Midodrine HCl (Randomized Phase)Midodrine HCl First, Then Placebo (Randomized Phase)
Started01010
Completed0910
Not completed010
Withdrew: Other010
Randomized Phase (Second Intervention)
Participant flow — Randomized Phase (Second Intervention)
MilestoneMidodrine HCl (Open-label Phase)Placebo First, Then Midodrine HCl (Randomized Phase)Midodrine HCl First, Then Placebo (Randomized Phase)
Started0910
Completed0910
Not completed000

Outcome measures

PrimaryTime to Onset of Syncope/Near Syncope While on Tilt Table

After a 30-minute supine period, the table was tilted from 0-90º within 30 seconds and maintained in that position for 45 minutes or until endpoint. Subjects were monitored for near-syncopal symptoms (subject felt sufficiently dizzy, lightheaded, faint, or felt like they were about to black out and requested the table to be returned to horizontal). Such a report ended the test. Alternatively, if the investigator observed that the subject was about to lose consciousness, that also constituted an endpoint.

Time frame:
1 hour post-dose
Reported as:
Least squares mean · seconds
Time to Onset of Syncope/Near Syncope While on Tilt Table
secondsPlaceboMidodrine HCl
Time to Onset of Syncope/Near Syncope While on Tilt Table1105.6 ± 186.821626.6 ± 186.82
Statistical analysis
  • Placebo vs Midodrine HCl · ANOVA · p = 0.0131 · Mean difference (final values): 521.0 · 95% CI 124.2 to 917.7

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Midodrine HCl (Open-label Phase)—0/24 (0%)3/24 (12.5%)
Placebo (Randomized Phase)—0/20 (0%)1/20 (5%)
Midodrine HCl (Randomized Phase)—0/20 (0%)1/20 (5%)
Most frequent other events
Most frequent other events
EventMidodrine HCl (Open-label Phase)Placebo (Randomized Phase)Midodrine HCl (Randomized Phase)
NauseaGastrointestinal disorders2/240/200/20
HeadacheNervous system disorders2/240/200/20
FatigueGeneral disorders0/240/201/20
Back PainMusculoskeletal and connective tissue disorders0/241/200/20
FlushingVascular disorders0/240/201/20
Hot FlushVascular disorders0/240/201/20

Baseline characteristics

Randomized Safety Analysis Set defined as all subjects who received at least 1 dose of randomized investigational product.

Age, Continuous
Age, Continuous(years)Placebo First, Then Midodrine HCl (Randomized Phase)Midodrine HCl First, Then Placebo (Randomized Phase)Total
Mean48.0 ± 19.5242.1 ± 18.6445.1 ± 18.82
Age, Customized
Age, Customized(Participants)Placebo First, Then Midodrine HCl (Randomized Phase)Midodrine HCl First, Then Placebo (Randomized Phase)Total
18 to 65 years, inclusive8816
>= 66 years224
Sex: Female, Male
Sex: Female, Male(Participants)Placebo First, Then Midodrine HCl (Randomized Phase)Midodrine HCl First, Then Placebo (Randomized Phase)Total
Female81018
Male202
Region of Enrollment
Region of Enrollment(Participants)Placebo First, Then Midodrine HCl (Randomized Phase)Midodrine HCl First, Then Placebo (Randomized Phase)Total
United States101020
08

Study locations

13 sites
  • Parkinson's Disease and Movement Disorders Center of Boca Raton
    Boca Raton, Florida 33486, United States
  • Advance Research Institute Inc
    New Port Richey, Florida 34653, United States
  • Analab Clinical Research Inc
    Lenexa, Kansas 66219, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Buffalo Clinical Research Center (BCRC)
    Buffalo, New York 14202, United States
  • NYU Medical Centre
    New York, New York 10016, United States
  • Columbia University
    New York, New York 10032, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Kidney and Hypertension Center
    Roseburg, Oregon 97471, United States
  • New Orleans Center for Clinical Research - Knoxville
    Knoxville, Tennessee 37920, United States
  • The Heartbeat Clinic, PA
    McKinney, Texas 75069, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
  • Aurora Cardiovascular Services
    Milwaukee, Wisconsin 53215, United States
09

References and documents

Publications

  • Smith W, Wan H, Much D, Robinson AG, Martin P. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res. 2016 Aug;26(4):269-77. doi: 10.1007/s10286-016-0363-9. Epub 2016 Jul 2. PubMed 27372462 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2012 to primary completion in Jun 2013, 13 months.

Results were first posted in Jul 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2012
First posted
Jan 26, 2012
StartActual
May 14, 2012
Primary completionActual
Jun 22, 2013
CompletionActual
Jun 22, 2013
Results first posted
Jul 31, 2014
Last update
Jun 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01518946
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jan 26, 2012
Start date
May 14, 2012
Primary completion
Jun 22, 2013
Completion
Jun 22, 2013
Results posted
Jul 31, 2014
Last update
Jun 8, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midodrine

Start the discussion